Back to Search

Elecoglipron for Chronic Kidney Disease

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

Recruiting Phase 3 Interventional Study
Chronic Kidney Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
7,000 (estimated)
Sponsor
AstraZeneca · Industry
Who this trial is looking for

This trial is looking for adults with chronic kidney disease to see how well elecoglipron works compared to a placebo. Participants must be on certain medications for their condition before joining the study.

Are You a Good Fit for This Trial?
Must be taking Dapagliflozin
Rules you out Type 1 diabetesPancreatitis

You may be able to join if

  • I have been diagnosed with chronic kidney disease.
  • I have an albumin-to-creatinine ratio of 30 mg/g or more.
  • I have an estimated glomerular filtration rate of 20 mL/min/1.73 m² or more.
  • I have been taking a stable dose of ACE inhibitor or ARB for at least 4 weeks.

You may not be able to join if

  • My body mass index (BMI) is less than 23 kg/m².
  • I have a history of type 1 diabetes.
  • My HbA1c is 10% or higher.
  • I am currently being treated for diabetic eye problems.
  • I have had severe low blood sugar more than once in the last 6 months.
  • I had a heart attack, stroke, or major cardiac procedure in the last 3 months.
  • I have a significant condition affecting my upper gastrointestinal tract.
  • I have a history of pancreatitis.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Adults with confirmed CKD; UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m² within specified ranges. * On stable, patient maximum tolerated, labeled daily dose of ACEI or ARB for ≥4 weeks at least 28 days before screening. Exclusion Criteria: * BMI \<23 kg/m² at screening * History…
Contacts

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

CONTACT

NCT ID: NCT07753993 Source: ClinicalTrials.gov